Appeals court reverses J&J decision

Share this article:
FDA's chief litigator said he is focusing on corporate chief executives for personal prosecution in cases of flagrant off-label product promotions. Agency deputy chief counsel for litigation Eric M. Blumberg told a Food & Drug Law Institute Enforcement and Litigation Conference in October that this area is a top priority under a rejuvenated strategy using the Park Doctrine, which holds CEOs liable even when they knew nothing about the offenses.
A West Virginia appeals court has reversed a lower court ruling and $4.5 million penalty against Johnson & Johnson for having allegedly made misleading statements in communications to doctors on its antipsychotic drug Risperdal and Duragesic fentanyl patch. The penalty was applied to a 2003 Janssen letter to doctors on Risperdal and a 2003 14-page promotional file card on Duragesic. The appeals court found that the lower court erred when it relied on a CDER Division of Drug Marketing, Advertising and Communications Warning Letter as evidence the communications were false and misleading. Because Warning Letters do not constitute “final agency action,” they are not susceptible to judicial review, the appeals court said.
“Accordingly, the circuit court erred in giving preclusive effect to the FDA's determinations that Janssen had violated the FDCA through its statements and omissions” in the Risperdal and Duragesic communications.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.